Although ICIs can elicit deep and durable responses in some patients affected by metastatic cancer, the ORR for ICI treatment obtained in mCRPC patients has been reported as 3% for patients with tumors without PD-L1 expression and 5% for those with PD-L1-expressing tumors [65]. Here, CD274 is linked to metastatic malignant neoplasm.